Our top pick for
Building a portfolio

Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
Avenue Therapeutics, Inc is a biotechnology business based in the US. Avenue Therapeutics shares (ATXI) are listed on the NASDAQ and all prices are listed in US Dollars. Avenue Therapeutics employs 4 staff and has a market cap (total outstanding shares value) of USD$104.3 million.
Our top pick for
Building a portfolio
Our top pick for
Beginners
Our top pick for
Mobile users
Latest market close | USD$6.29 |
---|---|
52-week range | USD$2.85 - USD$12.34 |
50-day moving average | USD$3.8938 |
200-day moving average | USD$8.1378 |
Wall St. target price | USD$9 |
PE ratio | N/A |
Dividend yield | N/A (0%) |
Earnings per share (TTM) | USD$-1.955 |
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $6.29 from 2020-12-18
1 week (2021-01-15) | 0.96% |
---|---|
1 month (2020-12-23) | -1.41% |
3 months (2020-10-23) | 81.79% |
6 months (2020-07-23) | -38.57% |
1 year (2020-01-23) | -29.52% |
---|---|
2 years (2019-01-23) | -1.41% |
3 years (2018-01-23) | 64.66% |
5 years (2016-01-19) | N/A |
Gross profit TTM | USD$0 |
---|---|
Return on assets TTM | -66.43% |
Return on equity TTM | -126% |
Profit margin | 0% |
Book value | $0.193 |
Market capitalisation | USD$104.3 million |
TTM: trailing 12 months
There are currently 345,757 Avenue Therapeutics shares held short by investors – that's known as Avenue Therapeutics's "short interest". This figure is 13% up from 306,076 last month.
There are a few different ways that this level of interest in shorting Avenue Therapeutics shares can be evaluated.
Avenue Therapeutics's "short interest ratio" (SIR) is the quantity of Avenue Therapeutics shares currently shorted divided by the average quantity of Avenue Therapeutics shares traded daily (recently around 142286.83127572). Avenue Therapeutics's SIR currently stands at 2.43. In other words for every 100,000 Avenue Therapeutics shares traded daily on the market, roughly 2430 shares are currently held short.
However Avenue Therapeutics's short interest can also be evaluated against the total number of Avenue Therapeutics shares, or, against the total number of tradable Avenue Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Avenue Therapeutics's short interest could be expressed as 0.02% of the outstanding shares (for every 100,000 Avenue Therapeutics shares in existence, roughly 20 shares are currently held short) or 0.1387% of the tradable shares (for every 100,000 tradable Avenue Therapeutics shares, roughly 139 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Avenue Therapeutics.
Find out more about how you can short Avenue Therapeutics stock.
We're not expecting Avenue Therapeutics to pay a dividend over the next 12 months.
Over the last 12 months, Avenue Therapeutics's shares have ranged in value from as little as $2.85 up to $12.34. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Avenue Therapeutics's is 0.5241. This would suggest that Avenue Therapeutics's shares are less volatile than average (for this exchange).
Avenue Therapeutics, Inc., a specialty pharmaceutical company, acquires, licenses, develops, and commercializes products primarily for use in the acute/intensive care hospital setting. Its product candidate is intravenous Tramadol, which is in Phase III clinical trials to treat moderate to moderately severe post-operative pain. The company was founded in 2015 and is based in New York, New York. Effective as of December 31, 2019, Avenue Therapeutics, Inc. operates as a subsidiary of InvaGen Pharmaceuticals, Inc.
Steps to owning and managing SSNC, with 24-hour and historical pricing before you buy.
Steps to owning and managing SMBC, with 24-hour and historical pricing before you buy.
Steps to owning and managing SMED, with 24-hour and historical pricing before you buy.
Steps to owning and managing SJW, with 24-hour and historical pricing before you buy.
Steps to owning and managing SFBS, with 24-hour and historical pricing before you buy.
Steps to owning and managing LEDS, with 24-hour and historical pricing before you buy.
Steps to owning and managing SC, with 24-hour and historical pricing before you buy.
Steps to owning and managing RTW, with 24-hour and historical pricing before you buy.
Steps to owning and managing RIVE, with 24-hour and historical pricing before you buy.
Steps to owning and managing RVSB, with 24-hour and historical pricing before you buy.